Literature DB >> 8984506

Insights into opioid action in the intestinal tract.

A De Luca1, I M Coupar.   

Abstract

Opioids have been used for centuries as antidiarrhoeal drugs. In recent years, their mechanism and sites of action in exerting their antidiarrhoeal effect have been studied intensely. Attempts have been made to propose their general mode of action. Whilst there are numerous similarities in their general effects on motility, fluid secretion, and neuroeffector transmission, the differences between species, in some cases, can be remarkable. We highlight and contrast the similarities and differences in the commonly examined species and compare them to humans. Insights into mechanisms of opioid antidiarrhoeal action now also provide some new perspectives of opioid action in the intestine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8984506     DOI: 10.1016/0163-7258(95)02053-5

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  70 in total

Review 1.  Management of opioid-induced bowel dysfunction in cancer patients.

Authors:  Antonio Cesar Tamayo; Paola Andrea Diaz-Zuluaga
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

2.  Opioids and efflux transporters. Part 1: P-glycoprotein substrate activity of N-substituted analogs of meperidine.

Authors:  Susan L Mercer; Hazem E Hassan; Christopher W Cunningham; Natalie D Eddington; Andrew Coop
Journal:  Bioorg Med Chem Lett       Date:  2006-12-21       Impact factor: 2.823

Review 3.  Indications for Opioid Antagonists.

Authors:  O J Michael Coppes; Christine N Sang
Journal:  Curr Pain Headache Rep       Date:  2017-06

4.  Opioid-Induced Esophageal Dysfunction (OIED) in Patients on Chronic Opioids.

Authors:  Shiva K Ratuapli; Michael D Crowell; John K DiBaise; Marcelo F Vela; Francisco C Ramirez; George E Burdick; Brian E Lacy; Joseph A Murray
Journal:  Am J Gastroenterol       Date:  2015-06-02       Impact factor: 10.864

5.  Methyl-orvinol-Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome.

Authors:  Marta Zielińska; Agata Jarmuż; Andrzej Wasilewski; Gerta Cami-Kobeci; Stephen Husbands; Jakub Fichna
Journal:  Pharmacol Rep       Date:  2016-12-05       Impact factor: 3.024

6.  The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.

Authors:  Pamela R Tsuruda; Ross G Vickery; Daniel D Long; Scott R Armstrong; David T Beattie
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-04       Impact factor: 3.000

Review 7.  Targeting TRPV1 as an alternative approach to narcotic analgesics to treat chronic pain conditions.

Authors:  Louis S Premkumar
Journal:  AAPS J       Date:  2010-05-04       Impact factor: 4.009

Review 8.  Racecadotril versus loperamide: antidiarrheal research revisited.

Authors:  S Huighebaert; F Awouters; G N J Tytgat
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

9.  Effect of thienorphine on intestinal transit and isolated guinea-pig ileum contraction.

Authors:  Pei-Lan Zhou; Yu-Lei Li; Ling-Di Yan; Zheng Yong; Gang Yu; Hua-Jin Dong; Hui Yan; Rui-Bin Su; Ze-Hui Gong
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

10.  Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation.

Authors:  Cornelius E J Sloots; An Rykx; Marina Cools; Rene Kerstens; Martine De Pauw
Journal:  Dig Dis Sci       Date:  2010-04-30       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.